Observational study suggests a role for Vifor's Ferinject for anemic and iron deficient patients with cancer

31 January 2013

Swiss firm Vifor Pharma, a subsidiary of the Galenica Group (GALN: SIX), notes the publication of an observational study in routine oncological and hematological settings encompassing anaemic and iron-deficient patients with a wide variety of tumours (420 subjects, efficacy population).

The study was recently published in the peer-reviewed journal Annals of Oncology. It contains the largest dataset published to date with Ferinject (ferric carboxymaltose), Vifor’s leading product, using real-life data. The treatment with Ferinject alone resulted in a substantial increase in hemoglobin (Hb) levels (median 1.4 g/dL) during the period of the study. Hb levels improved steadily and remained stable (> 11 g/dL) from week five onwards. These important results follow a review by Aapro et al highlighting the prevalence, appropriate diagnosis and management of cancer-related anemia.

32%-60% of cancer patients have iron deficiency

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK